Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
84 hedge funds and large institutions have $243M invested in Adamas Pharmaceuticals in 2016 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 23 reducing their positions, and 14 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 3 → 6 (+3)
30% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 23
17% more capital invested
Capital invested by funds: $207M → $243M (+$36M)
0% more funds holding
Funds holding: 84 → 84 (0)
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $332K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.95M |
| 2 |
BS
Bow Street
New York
|
+$8.02M |
| 3 |
BWCA
Brenner West Capital Advisors
New York
|
+$7.81M |
| 4 |
BOS
Bingham Osborn & Scarborough
San Francisco,
California
|
+$3.38M |
| 5 |
JGC
J. Goldman & Co
New York
|
+$2.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$7.83M |
| 2 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$3.3M |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
-$1.69M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
-$1.65M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.57M |
ADMS Hedge Fund Activity: Q2 2016 in Review
84 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2016, worth a combined $243M — up 17% from $207M a quarter earlier.
Fund positioning in ADMS was balanced in Q2 2016: 14 funds opened new positions, 14 closed out, 30 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, adding an estimated $8.95M. The largest seller was Gilder Gagnon Howe & Co, exiting entirely with an estimated $7.83M sold.
- 84 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $243M of Adamas Pharmaceuticals stock for Q2 2016, up 17% quarter-over-quarter.
- 14 funds opened new Adamas Pharmaceuticals positions in Q2 2016 and 14 closed out, a net change of 0 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2016 was Millennium Management, an estimated $8.95M added.
- The largest Adamas Pharmaceuticals seller in Q2 2016 was Gilder Gagnon Howe & Co, an estimated $7.83M sold.
Based on aggregated 13F filings for Q2 2016.